- Cook, Christopher P;
- Taylor, Mark;
- Liu, Yale;
- Schmidt, Ralf;
- Sedgewick, Andrew;
- Kim, Esther;
- Hailer, Ashley;
- North, Jeffrey P;
- Harirchian, Paymann;
- Wang, Hao;
- Kashem, Sakeen W;
- Shou, Yanhong;
- McCalmont, Timothy C;
- Benz, Stephen C;
- Choi, Jaehyuk;
- Purdom, Elizabeth;
- Marson, Alexander;
- Ramos, Silvia BV;
- Cheng, Jeffrey B;
- Cho, Raymond J
The homeostatic mechanisms that fail to restrain chronic tissue inflammation in diseases, such as psoriasis vulgaris, remain incompletely understood. We profiled transcriptomes and epitopes of single psoriatic and normal skin-resident T cells, revealing a gradated transcriptional program of coordinately regulated inflammation-suppressive genes. This program, which is sharply suppressed in lesional skin, strikingly restricts Th17/Tc17 cytokine and other inflammatory mediators on the single-cell level. CRISPR-based deactivation of two core components of this inflammation-suppressive program, ZFP36L2 and ZFP36, replicates the interleukin-17A (IL-17A), granulocyte macrophage-colony-stimulating factor (GM-CSF), and interferon gamma (IFNγ) elevation in psoriatic memory T cells deficient in these transcripts, functionally validating their influence. Combinatoric expression analysis indicates the suppression of specific inflammatory mediators by individual program members. Finally, we find that therapeutic IL-23 blockade reduces Th17/Tc17 cell frequency in lesional skin but fails to normalize this inflammatory-suppressive program, suggesting how treated lesions may be primed for recurrence after withdrawal of treatment.